FDA approves KALYDECO (VX-770), the first medicine to treat the underlying cause of cystic fibrosis

Vertex Pharmaceuticals Incorporated announced today that the U.S. Food and Drug Administration (FDA) has approved KALYDECO^TM (VX-770) for the treatment of cystic fibrosis in individuals ages 6 and older who have at least one copy of the G551D CF mutation. Read more or listen to the company’s webcast.

Reviewed/updated: 2012-01-31